CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women

NCT ID: NCT05336825

Last Updated: 2022-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-01

Study Completion Date

2021-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CO2 laser energy is currently used widely for the treatment of postmenopausal women who have vaginal atrophy due to the lack of estrogen. However, its effect on premenopausal women with hormonally-mediated vulvar vestibulodynia is unknown. This study seeks to evaluate the effect of CO2 laser on young women and compare it to topical lidocaine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to see if vaginal laser therapy with MonaLisa Touch® will be more effective in treating vestibulodynia than current treatment with a topical lidocaine ointment. Vestibulodynia is a common bothersome condition and is more likely to occur in women on hormonal contraceptive treatment. To date, there are no effective treatments that address the underlying causes of the disease. MonaLisa Touch® is a laser procedure that delivers CO2 laser energy to the vaginal wall tissue. This energy causes the patient's own body to regenerate collagen and blood vessels, changing the tissue to make it healthier. The MonaLisa Touch® technology may help vestibulodynia by potentially fixing the underlying cause. This may be more effective than using the topical lidocaine which makes the tissue numb.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vulvodynia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CO2 laser

Mona Lisa CO2 laser will be applied externally to the vulvar vestibule in three sessions over a three month period.

Group Type EXPERIMENTAL

CO2 laser

Intervention Type DEVICE

Mona Lisa CO2 laser

Lidocaine

5% topical lidocaine will be applied nightly via a cotton square in participants

Group Type ACTIVE_COMPARATOR

Lidocaine patch 5%

Intervention Type DRUG

lidocaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CO2 laser

Mona Lisa CO2 laser

Intervention Type DEVICE

Lidocaine patch 5%

lidocaine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years to 40 years
* Hormonal contraceptive therapy for at least one year consecutive duration
* Vestibulodynia diagnosis meeting the following criteria:

* Localized vulvar pain to vaginal vestibule
* At least 3 months duration
* Without clear identifiable cause

Exclusion Criteria

* Suspected primary cause to vestibular pain that warrants directed treatment
* History of chronic infection or autoimmune disease
* Prior pelvic surgery including mesh placement for incontinence or prolapse, vestibulectomy, vulvectomy, or labiaplasty
* Active vulvar or vaginal infection
* Allergy or contraindication to topical lidocaine treatment
* Prior diagnosis or treatment of vulvar intraepithelial neoplasia or vulvar malignancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Foundation for Morristown Medical Center

UNKNOWN

Sponsor Role collaborator

Atlantic Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Ingber

Director of The Center for Specialized Women's Health, division of Garden State Urology/Atlantic Health System

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Garden State Urology

Denville, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GSU-MLT001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Photodynamic Therapy for Permanent Hair Removal
NCT00371930 UNKNOWN PHASE1/PHASE2